Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View Item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Health economic impact of liquid biopsies in cancer management.

Thumbnail
View/Open
Accepted version (915.4Kb)
Publication Date
2018-12
ICR Author
De Bono, Johann
Author
IJzerman, MJ
Berghuis, AMS
de Bono, JS
Terstappen, LWMM
Type
Journal Article
Metadata
Show full item record
Abstract
<h4>Introduction</h4>Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed. Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. We conclude with a future perspective on the clinical use and reimbursement of LBs Expert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits. This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.
URL
https://repository.icr.ac.uk/handle/internal/2937
Collections
  • Clinical Studies
Licenseref URL
http://www.rioxx.net/licenses/under-embargo-all-rights-reserved
Version of record
10.1080/14737167.2018.1505505
Subject
Humans
Neoplasms
Breast Neoplasms
Disease Progression
Reimbursement Mechanisms
Female
Neoplastic Cells, Circulating
Biomarkers, Tumor
Liquid Biopsy
Research team
Prostate Cancer Targeted Therapy Group
Language
eng
License start date
2018-12
Citation
Expert review of pharmacoeconomics & outcomes research, 2018, 18 (6), pp. 593 - 599

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.